Opioid use disorder

Innovative, high-quality research to benefit all Canadians gets major investment

Retrieved on: 
Wednesday, March 13, 2024
Health, Government, Brain, Transport, MRI, CFI, Wheelchair, Environment, Disease, Partnership, COVID-19, PET, The Honourable, Research, Infrastructure, University, Opioid use disorder, Student, Investment, Quebec lieutenant, Disability, Medicine, Snow, Renewable energy

He made the announcement on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.

Key Points: 
  • He made the announcement on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.
  • The funding will support 100 infrastructure projects at 32 postsecondary institutions and research hospitals across the country and will help Canada remain at the forefront of exploration, discovery and innovation.
  • Other exceptional research infrastructure projects this funding supports include:
    Repurposing drugs to treat opioid use disorder.
  • Researchers will collaborate with people with lived experience of opioid use to repurpose existing drugs to treat the disorder’s debilitating symptoms.

Middlesex Recovery Earns Three-Year CARF Accreditation

Retrieved on: 
Tuesday, March 12, 2024
Health, Organization, Opioid use disorder, Commission, Senior counsel, CARF, Accreditation, Person, Nursing

LEWISVILLE, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Middlesex Recovery is proud to announce that it has earned a Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Office-Based Opioid Treatment: Addictions Pharmacotherapy (Adults) programs, located in Chelmsford, Gloucester, Norton, Stoughton, Woburn, MA and Salem, NH.

Key Points: 
  • LEWISVILLE, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Middlesex Recovery is proud to announce that it has earned a Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Office-Based Opioid Treatment: Addictions Pharmacotherapy (Adults) programs, located in Chelmsford, Gloucester, Norton, Stoughton, Woburn, MA and Salem, NH.
  • This designation represents the highest level of recognition that can be given to an organization and shows Middlesex Recovery’s substantial conformance to the CARF standards.
  • An organization receiving a Three-Year Accreditation has gone through a rigorous peer-review process.
  • Middlesex Recovery is managed by BayMark Health, with treatment centers in Massachusetts and southern New Hampshire.

YesCare has Joined Leading Multiagency Initiative on Opioid Use

Retrieved on: 
Tuesday, April 2, 2024
Public Policy, Government, Law Enforcement, Emergency Services, Mental Health, State, Local, Health, Managed Care, General Health, Mental health, Policy, SAMHSA, Partnership, ADOC, Prison, MAT, Public, Patient, Recidivism, Psychological abuse, Opioid use disorder, Federal Prison Camp, Pensacola, Senior counsel, Lean Six Sigma, Opioid, Substance Abuse, Nursing

This multiagency initiative focused on Medication Assisted Treatment (MAT) in prisons will be a collaboration led by SAMHSA (the federal agency charged with advancing behavioral health since 1992) along with YesCare, ADOC, the Alabama Department of Mental Health, the Alabama Board of Pardons and Parole, and the State Opioid Treatment Authority.

Key Points: 
  • This multiagency initiative focused on Medication Assisted Treatment (MAT) in prisons will be a collaboration led by SAMHSA (the federal agency charged with advancing behavioral health since 1992) along with YesCare, ADOC, the Alabama Department of Mental Health, the Alabama Board of Pardons and Parole, and the State Opioid Treatment Authority.
  • The Policy Academy is a part of the Biden-Harris Administration's efforts to address the opioid overdose epidemic and to support recovery among Americans experiencing substance use disorders.
  • “Through this partnership, Alabama will be on the leading edge of MAT implementation, and success here will allow for an optimized roll out of improved programs nationwide,” said Jeff Sholey, CEO of YesCare.
  • “To be selected by SAMHSA for this initiative reflects a true testament to the partnership we share with ADOC, and the common dedication we have in helping those with Opioid Use Disorders.

Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Aromatherapy, National Consumers League, Hydrocodone, MAPDA, NCL, Partnership, Mother, Education, Patient, Yoga, Paracetamol, Opioid use disorder, Naproxen, Trial of the century, Bayer, Meditation, OTC, CDC, Love, Pain, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240325938118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325938118/en/
    Aleve launches "The Painful Truth" campaign with Mothers Against Prescription Drug Abuse (MAPDA) and National Consumers League (NCL).
  • (Photo: Business Wire)
    While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries.
  • “The Painful Truth” campaign launches with a three-minute film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance.
  • At this critical juncture in their care, the patients are encouraged to consider different pain relief options.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Retrieved on: 
Thursday, March 14, 2024
Patient, Public, OUD, Research, Columbia University, Opioid use disorder, IND, GMP, Report, Ibogaine, Toxicology, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders. As summarized in a recent New York Times article (Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction), ibogaine, a plant-derived psychoactive compound, has accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.

Key Points: 
  • However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.
  • This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials in healthy volunteers and opioid use disorder (OUD) patients for GM-3009.
  • The planned clinical work will seek to confirm that GM-3009 eliminates the cardiovascular risks associated with ibogaine and demonstrate proof-of-concept efficacy in attenuating symptoms associated with OUD.
  • As Gilgamesh moves forward with its clinical trials, the company is poised to lead a new era in addiction treatment, marked by safer, more effective, and scientifically validated therapies.

Telehealth addiction treatment offers exceptional outcomes for pregnant people with opioid use disorder

Retrieved on: 
Thursday, March 14, 2024
ANN, Health, Patient, OUD, Research, Buprenorphine, Mortality, Opioid use disorder, Pregnancy, Small business, American College, Drug, MPH, Privacy, Mortal Kombat, Dietary supplement

ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Workit Labs, the research and development arm of Workit Health, today published a promising analysis of patients who were pregnant and received telehealth treatment for opioid use disorder. As opioid use disorder (OUD) is a growing risk factor for perinatal death, research in this field is increasingly vital.

Key Points: 
  • ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Workit Labs, the research and development arm of Workit Health, today published a promising analysis of patients who were pregnant and received telehealth treatment for opioid use disorder.
  • As opioid use disorder (OUD) is a growing risk factor for perinatal death, research in this field is increasingly vital.
  • It can be challenging for people who are pregnant and living with opioid use disorder to find addiction treatment.
  • "It can be extremely challenging for people who are pregnant and living with opioid use disorder to find addiction treatment," said Lira.

FORE Awards New Grant to Address Impact of Post-COVID Medicaid Policy Changes on Access to Treatment for Opioid Use Disorder

Retrieved on: 
Thursday, March 7, 2024
Opioid use disorder, Opioid, Drug, Risk, COVID-19, Buprenorphine, Organization, Policy, Patient, Pharmaceutical industry

“Medicaid is the single largest payer for opioid use disorder treatment and a lifeline for people who are often at the highest risk of overdose,” said Karen A. Scott, MD, MPH., president of FORE.

Key Points: 
  • “Medicaid is the single largest payer for opioid use disorder treatment and a lifeline for people who are often at the highest risk of overdose,” said Karen A. Scott, MD, MPH., president of FORE.
  • This latest grant builds on previous support RAND received from FORE for projects to understand the impact of policy changes for prescribing and accessing buprenorphine treatment during COVID-19.
  • FORE was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nation’s opioid crisis.
  • FORE’s mission is to support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid use disorder, their families, and their communities.

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Retrieved on: 
Wednesday, February 28, 2024
OUD, Opioid use disorder, Intellectual property, Patent, Pharmaceutical industry

CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.

Key Points: 
  • CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.
  • The patent covers the Company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder (OUD).
  • “We are proud to be awarded another important patent that broadens our Intellectual Property portfolio and covers meaningful aspects of our lead asset, AD04, including its unique ability to target the serotonin transporter gene,” commented Cary Claiborne, CEO of Adial Pharmaceuticals.
  • “We believe AD04 has significant potential to treat OUD and other drug dependencies in addition to our initial indication of alcohol use disorder.